Dutasteride Twice or Three Times Weekly vs Daily Finasteride: 2025 Pilot RCT Research Summary

Last verified: Apr 2026Oral DutasterideLimited evidence

This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.

Original research published in JAAD International, 2025

Dutasteride Twice or Three Times Weekly vs Daily Finasteride

Read original →

Study conclusion

Small pilot trial of 60 men tested whether dutasteride 0.5mg two or three times per week could increase hair growth while potentially reducing side effects vs daily finasteride. All three regimens increased hair density and diameter significantly. Three-times-weekly dutasteride showed greater improvement than twice weekly but did not significantly outperform daily finasteride in hair count.

Strength of evidence

Strength of evidence
Limited evidence · 5/10

This was a randomised investigator-blinded pilot trial. The score is limited because the sample was only 60 men, it was conducted at a single centre, the trial was not blinded to participants, and dutasteride is not FDA-approved for hair loss. Pilot studies are by design preliminary.

Who it applies to

Who was studied

Men aged 21–60 with mild to moderate pattern hair loss. 60 participants randomised equally. Dutasteride 0.5mg twice weekly, dutasteride 0.5mg three times weekly, or finasteride 1mg daily for 24 weeks.

Who was NOT studied

Women. Men with severe hair loss. People using higher or different dosing schedules.

What to look for when shopping

Dutasteride is not FDA-approved for hair loss. Finasteride 1mg is the only FDA-approved oral treatment. Both are prescription-only.

What research cannot help you decide

Whether intermittent dutasteride reduces sexual side effects vs daily finasteride. The trial was not powered to detect side effect differences.

Key findings

  • All three regimens significantly increased hair density and diameter from baseline
  • Dutasteride three times weekly showed greater improvement in hair density and diameter than twice weekly
  • Dutasteride three times weekly did not significantly outperform daily finasteride in total hair count
  • Mean terminal hair count increase was 17.43 hairs/cm² for 3x/week dutasteride vs 12.81 hairs/cm² for daily finasteride
  • Sexual side effects were similar across all three groups

What they did

Researchers randomly assigned 60 men with mild to moderate pattern hair loss to dutasteride 0.5mg twice weekly, dutasteride 0.5mg three times weekly, or finasteride 1mg daily for 24 weeks at a single Thai university hospital. Hair density and diameter were measured using videodermoscopy. Investigators were blinded to treatment allocation; participants were not.

What they found

ComparisonResultSignificant?
Dutasteride 3x/week vs finasteride daily — hair countNon-significantly higher with dutasteride (17.43 vs 12.81 hairs/cm²)No
Dutasteride 3x/week vs 2x/week — hair density and diameterSignificantly better with 3x/weekYes
All three groups vs baseline — hair densityAll three showed significant improvementYes
Sexual side effects — all groupsSimilar across all three regimensNo

What this study does not show

  1. 1.Whether intermittent dutasteride reduces sexual side effects. The study was too small to detect this.
  2. 2.Whether results would hold in a larger confirmatory trial.
  3. 3.How intermittent dutasteride compares to daily dutasteride 0.5mg.
  4. 4.Long-term outcomes beyond 24 weeks.

Limitations

  1. 1.Only 60 participants — a very small pilot study
  2. 2.Single-centre study conducted in Thailand
  3. 3.Participants were not blinded to treatment allocation
  4. 4.Dutasteride is not FDA-approved for hair loss
  5. 5.Pilot study by design — conclusions are preliminary

Who funded it

Funded by the Faculty of Medicine, Srinakharinwirot University. No commercial conflicts of interest declared.

Used in these articles

Links added as fact-checks and articles citing this study are published.